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Background: There is a lack of standardized definition for treatment-related mortality (TRM), which represents an
important endpoint in cancer. Our objective was to describe TRM definitions used in studies of children, adolescents
and young adults with lymphomas, solid tumors and brain tumors.
Methods: We conducted a systematic review of studies enrolling children, adolescents and young adults with
lymphomas, solid tumors and brain tumors in which an anti-cancer intervention was randomized, or all study designs
in which TRM was a primary or secondary outcome. We searched Ovid MEDLINE, EMBASE and Evidence-Based
Medicine Reviews from 1980 to June 2013. Two reviewers evaluated study eligibility and abstracted data.
Results: In total, 67 studies were included and consisted of 62 randomized therapeutic trials and 5 TRM studies. None
of the studies (0/67) provided a definition for TRM. Only one randomized trial of rhabdomyosarcoma provided a
definition of early death.
Conclusions: We were unable to identify any TRM definitions used in studies of children, adolescents and young
adults with lymphomas, solid tumors and brain tumors. Given that a proportion of this patient population may receive
intensive treatment, there is an urgent need for consensus-based definitions of TRM for use across clinical trials.
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Treatment-related mortality (TRM) is essential information
for physicians involved in the care of children, adolescents
and young adults with cancer. Outcomes for pediatric can-
cer have improved remarkably over time and the 5-year
overall survival rate for childhood cancers currently exceeds
80% [1]. However, many children with cancer still die and
cancer remains the second most common cause of death
for North American children and adolescents (after acci-
dents) [1,2]. As cure rates continue to improve, TRM is
predicted to account for a growing proportion of deaths in
this population [3].* Correspondence: lillian.sung@sickkids.ca
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unless otherwise stated.Describing and identifying predictors of TRM are criti-
cally important. Appreciating TRM versus disease-related
death is fundamental to understanding the best strategy to
improve overall survival. For instance, if TRM is the pri-
mary cause of failure for a specific cancer, then the strategy
must focus on enhancing supportive care and/or using less
toxic therapies [1]. Conversely, if disease progression is the
primary cause of death, efforts could be directed towards
identification of novel therapies to improve disease control.
In addition, correct identification of TRM and disease-
related mortality allows for appropriate monitoring of out-
comes between trials and over time.
In spite of the critical importance of TRM, epidemio-
logical investigation into TRM characteristics and risk fac-
tors has been crippled by the lack of a standardized
definition for TRM. We previously published a systematicd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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stand the frequency with which TRM has been defined
and to describe the utilized definitions. We found most
pediatric acute leukemia trials do not describe how TRM
was defined and when described, we found great hetero-
geneity of TRM definitions across trials [4]. In order to
comprehensively assess TRM definition across all child-
hood cancers, we performed a systematic review of ran-
domized therapeutic trials of populations omitted in our
previous review, namely trials involving children, adoles-
cents and young adults being treated for lymphomas, solid
tumors and brain tumors. Our objectives were (1) to deter-
mine the frequency with which TRM has been defined;
and (2) to describe the utilized TRM definitions among
studies of lymphomas, solid tumors and brain tumors.
Methods
Data sources and searches
We developed a protocol for review and followed PRISMA
(Preferred Reporting Items for Systematic reviews and
Meta-Analysis) guidelines [5]. We performed comprehen-
sive searches for relevant trials using Ovid MEDLINE and
EMBASE from 1980 to June 2013 and Evidence-Based
Medicine (EBM) reviews-Cochrane Central Register of
Controlled Trials from 1980 to the second quarter of 2013,
without restriction of language or publication status. The
search strategy included the following medical subject
heading terms: “neoplasms”, “drug therapy”, “combined
modality therapy”, “treatment-related mortality”, “rando-
mized controlled trial”, “treatment mortality”. We also
included multiple synonyms, abbreviations, and related
keywords for each of these terms. The search strategy
can be found in Additional file 1. We focused on two
types of studies, namely: (1) trials in lymphoma, solid
tumor or brain tumor patients in which an anti-cancer
intervention was applied in a randomized fashion; and (2)
any type of study with TRM as a primary or secondary out-
come. We also examined the reference lists of retrieved ori-
ginal and review articles. As this study was a systematic
review of primary studies, no ethical approval was required.
Study selection
Inclusion and exclusion criteria were defined a priori.
Randomized therapeutic trials were included if: (1) study
was comprised solely of children, adolescents or young
adults (age defined by each study but generally included
patients up to 30 years of age); (2) population consisted of
newly diagnosed lymphoma, solid tumor or brain tumor
patients (ie. not relapsed); (3) there was randomization of
anti-cancer treatment (to ensure the study was conducted
prospectively) including radiotherapy and surgery alone;
and (4) treatment did not consist of solely of hematopoietic
stem cell transplantation (HSCT). Exclusion criteria were
as follows: (1) no randomized intervention; (2) randomizedintervention related to leukemia/myelodysplastic syndrome
(MDS) treatment; (3) study included adult subjects above
the age of 30; (4) report contained results of more than
one, separate randomized controlled trial (RCT) (ie. a re-
view); (5) phase 1 trial; (6) duplicate publication; (7) pub-
lished before 1990; (8) non-English publication; and (9)
abstract form only. When duplicate studies were identified,
the publication with the longest follow-up was chosen. For
studies in which TRM was an outcome, they were included
if: (1) study was comprised solely of children, adolescents
or young adults up to the age of 30; (2) population con-
sisted of all types of cancers (3) TRM was a primary or
secondary outcome; (4) treatment did not consist solely of
HSCT. Exclusion criteria were similar to those of thera-
peutic randomized trials except that randomization was not
required.
One reviewer (LS, ML or THT) screened the titles and
abstracts of publications identified by the search strategy.
Articles thought to be potentially eligible were retrieved in
full and each of these articles was independently assessed
for eligibility by two reviewers (ML and THT). Final inclu-
sion of studies into the systematic review was by agree-
ment of both reviewers and discrepancies were resolved
by consensus. The reviewers were not blinded to study
authors or outcomes. Data abstraction was performed by
two reviewers (ML and THT) using standardized data
collection form.
Outcome measures and definitions
The outcome of interest was the presence of TRM defini-
tions in studies of children, adolescents and young adults
with lymphomas, solid tumors and brain tumors and if
present, to describe how these definitions were defined. We
also looked at the reporting of the following variables of
interest when considering TRM: whether TRM over entire
treatment course was described, reporting of deaths before
starting treatment, deaths after completing treatment,
deaths after HSCT and deaths from accidents, suicide or
unknown cause.
Results and discussion
Figure 1 illustrates the flow diagram of trial identifica-
tion and selection. A total of 19,129 titles and abstracts
were reviewed; 131 full articles were retrieved for detailed
evaluation, and 67 satisfied eligibility criteria to be included
in the systematic review. Of these studies, 62 were ran-
domized therapeutic studies and 5 were studies in which
TRM was a primary or secondary outcome. Reasons for
exclusion are detailed in Figure 1.
Table 1 summarizes the data related to TRM definitions
among the two types of studies. None of the therapeutic
randomized trials or TRM studies provide a definition of
TRM for this population. Of these studies, one study did
refer to the concept of early death. This multicenter
Figure 1 Flow diagram illustrating flow of studies identified by search strategy and reasons for exclusion.
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Study Group (IRSG) defined early death as any death
occurring within 6 weeks of treatment initiation [6].
In addition, 12 therapeutic and 3 TRM studies reported
their TRM rate. Thirteen studies evaluated it over the entire
treatment course while 2 reported it by phase of therapy
(for example; during induction, maintenance or the radio-
therapy period). Among therapeutic studies, TRM rates
ranged from 0.2% to 7.0% (mean 2.7%) in these patient
populations that consisted of neuroblastoma (n = 996),
rhabdomyosarcoma (n = 2073), medulloblastoma (n = 364),
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the number of studies that report deaths occurring after
completing treatment, after HSCT, and deaths from acci-
dents, suicide and of unknown cause.
This systematic review demonstrates the absence of
TRM definitions identified in studies of children, adoles-
cents and young adults with lymphomas, solid tumors
and brain tumors. Moreover, it highlights heterogeneity
in reporting of deaths among these studies.
Although there is an overall lack of TRM definitions in
pediatric cancer studies, TRM appears to be more often
defined in pediatric acute leukemia trials than those of
lymphomas, solid tumors and brain tumors. Our previous
systematic review reported that 6.3% of pediatric acute
lymphoblastic leukemia (ALL) and 66.7% of pediatric
acute myeloid leukemia (AML) studies provided defini-
tions for TRM, in contrast to the complete absence of
TRM definitions in studies involving lymphoma, solid
tumor and brain tumor patients [4]. Similarly, while early
deaths was often used and defined in acute leukemia trials,
this concept was only identified in one randomized trial of
solid tumor patients [4]. In that particular study, the au-
thors used a cut-off of 6 weeks from treatment initiation
to define early death, a common time frame to delineate
death as early in pediatric AML studies.
TRM represents an important outcome that may im-
pact on patient management as well as therapeutic
trial design. An example in pediatric oncology where
TRM has been important is in children with Down
syndrome and ALL (DS-ALL). The observation of exces-
sive treatment-related deaths in these children from infec-
tions caused by chemotherapy-induced myelosuppression
has led to treatment modifications specifically for children
with DS-ALL [7-9]. These consisted of reducing therapy
intensity in addition to enhancing supportive care (for
example, leucovorin rescue, early empiric antibiotics, and
admission during neutropenic episode) which has contrib-
uted to improving survival [10]. In contrast, children with
DS and AML do not experience excess treatment-related
death when treated with standard AML chemotherapy
protocol developed for the general pediatric population
but appear to have a favorable infectious profile when
treated with DS-specific protocols for AML [11]. Knowing
TRM rates in children with DS-ALL and DS-AML has
lead to the adoption of specific strategies to improve out-
come for both groups. Hence, defining and understanding
TRM accurately serve as the foundation to adequately
balance between therapy modification and supportive care
implementation.
Another example to emphasize the importance of TRM
can be appreciated from Head Start III (HS-III), a non-
randomized, prospective, multi-institutional clinical trial
evaluating the feasibility of an intensive induction followed
by myeloablation with autologous hematopoietic stem cellrescue for young children with previously untreated malig-
nant brain tumors. In January 2007, Regimen D of HS-III
was suspended by the Data Safety Monitoring Committee
pending review of the treatment-related deaths among
children less than 18 months of age treated on this arm. Of
the 19 patients, five died during induction from treatment
toxicity. Causes of death were infections (n = 4), myocarditis
(n = 1) and hemorrhage not related to disease (n = 1)
[12]. In October 2007, the study reopened with reduction
in chemotherapy doses in addition to more rigorous sup-
portive care requirements. In light of the significance of
TRM, there is an urgent need to develop a consistent
definition of TRM for use across trials. Ideally, the same
definition could be used for both hematologic and solid
malignancies. Another important endeavor is to identify a
consistent cause-of-death attribution system for TRM
which will highlight the different distributions for deaths
on and off treatment. However, determining the cause of
death can represent a challenge due to the complexity of
the disease and inter-individual interpretations. Therefore,
a consensus approach will be adopted to develop a TRM
algorithm that can be reliably operated across different
abstractors, protocols, institutions and countries.
This review has unique strengths. To the best of our
knowledge, it is the first to systematically evaluate and
describe TRM definitions in studies of children, adoles-
cents and young adults with lymphomas, solid tumors
and brain tumors. Inclusion of studies from 1990 and
forward captures more recent TRM definitions in more
current trials and provides a more accurate estimate of
TRM definition use. However, similar to other systematic
reviews, it is limited by the methodological quality and
outcome reporting of the included studies. Also, we did
not include studies published in languages other than
English. It is possible that these publications had a greater
focus on TRM.
Conclusions
In conclusion, this systematic review reports the absence
of TRM definitions among studies of children, adoles-
cents and young adults with lymphomas, solid tumors
and brain tumors. As a better understanding of TRM is
crucial in choosing specific strategies to improve survival
of children with cancers, further work should prioritize
the development of a consistent TRM definition that
can be used across different diagnoses categories. A con-
sensus approach is likely the best approach to create
such a definition.Additional file
Additional file 1: Search strategies. Strategies used to perform
comprehensive searches for relevant trials.
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